AMT-210 / uniQure - LARVOL DELTA

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) - "...the Company hosted a virtual Research & Development Day to highlight new investments in its expanding gene therapy pipeline focusing on central nervous system and rare, liver-directed disorders, as well as new advancements in platform technology and manufacturing. Three new, internally developed pre-clinical programs were announced in Parkinson’s disease (AMT-210), Parkinson’s disease (AMT-210), amyotrophic lateral sclerosis (ALS) (AMT-161), and autosomal dominant Alzheimer’s disease (AMT-240)."

Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease